

United States Patent and Trademark Office

UNITED STATES DEPARTMENT OF COMMERCE United States Patent and Trademark Office Address: COMMISSIONER FOR PATENTS P.O. Box 1450 Alexandria, Virginia 22313-1450 www.uspto.gov

APPLICATION NO. FILING DATE FIRST NAMED INVENTOR ATTORNEY DOCKET NO. CONFIRMATION NO. 09/719,410 12/12/2000 0206-UTL-9 8826 **Burkhard Goke EXAMINER** 04/20/2005 7590 ARNOLD & PORTER MOHAMED, ABDEL A Attn: IP Docketing Departement, Room 1126B ART UNIT PAPER NUMBER 555 Twelfth Street, NW Washington, DC 20004-1206 1653

DATE MAILED: 04/20/2005

Please find below and/or attached an Office communication concerning this application or proceeding.

Advisory Action Before the Filing of an Appeal Brief

| Application No. | Applicant(s) |
|------------------|--------------|
| 09/719,410 | GOKE ET AL. |
| Examiner | Art Unit |
| Abdel A. Mohamed | 1653 |

| Belove the timing of an Appear Brief | Examiner | Art Unit | | |
|--|---|---|---------------------------------------|--|
| | Abdel A. Mohamed | 1653 | | |
| The MAILING DATE of this communication appears on the cover sheet with the correspondence address | | | | |
| THE REPLY FILED 28 March 2005 FAILS TO PLACE THIS AI | PPLICATION IN CONDITION FOR | ALLOWANCE. | | |
| The reply was filed after a final rejection, but prior to or o this application, applicant must timely file one of the following the application in condition for allowance; (2) a No. (3) a Request for Continued Examination (RCE) in comparing time periods: | n the same day as filing a Notice of owing replies: (1) an amendment, a otice of Appeal (with appeal fee) in liance with 37 CFR 1.114. The replications | f Appeal. To avoid at ffidavit, or other evide compliance with 37 (| ence, which CFR 41.31; or | |
| a) | risory Action, or (2) the date set forth in th | | er is later. In no | |
| Examiner Note: If box 1 is checked, check either box (a) or (b) MONTHS OF THE FINAL REJECTION. See MPEP 706.07(f | | RST REPLY WAS FILE | OWT NIHTIW C | |
| Extensions of time may be obtained under 37 CFR 1.136(a). The date on been filed is the date for purposes of determining the period of extension a CFR 1.17(a) is calculated from: (1) the expiration date of the shortened stabove, if checked. Any reply received by the Office later than three month earned patent term adjustment. See 37 CFR 1.704(b). NOTICE OF APPEAL | and the corresponding amount of the fee, atutory period for reply originally set in the | The appropriate extension final Office action; or (2) | n fee under 37 as set forth in (b) | |
| The Notice of Appeal was filed on A brief in com of filing the Notice of Appeal (37 CFR 41.37(a)), or any e Since a Notice of Appeal has been filed, any reply must I | extension thereof (37 CFR 41.37(e) |), to avoid dismissal o | of the appeal. | |
| AMENDMENTS | | | | |
| 3. The proposed amendment(s) filed after a final rejection, but prior to the date of filing a brief, will <u>not</u> be entered because (a) They raise new issues that would require further consideration and/or search (see NOTE below); (b) They raise the issue of new matter (see NOTE below); | | | | |
| (c) ☐ They are not deemed to place the application in be appeal; and/or | tter form for appeal by materially re | educing or simplifying | the issues for | |
| (d) They present additional claims without canceling a NOTE: (See 37 CFR 1.116 and 41.33(a)) | | jected claims. | | |
| 4. The amendments are not in compliance with 37 CFR 1. | | ompliant Amendment | (PTOL-324) | |
| 5. Applicant's reply has overcome the following rejection(s | | | (1.102.02.1). | |
| Newly proposed or amended claim(s) would be a the non-allowable claim(s). | allowable if submitted in a separate | · | - | |
| 7. For purposes of appeal, the proposed amendment(s): a) how the new or amended claims would be rejected is profit The status of the claim(s) is (or will be) as follows: Claim(s) allowed: <u>55-58</u> . Claim(s) objected to: Claim(s) rejected: <u>10-38,41,44-46 and 48-54</u> . | | ill be entered and an | explanation of | |
| Claim(s) withdrawn from consideration: AFFIDAVIT OR OTHER EVIDENCE | | | | |
| The affidavit or other evidence filed after a final action, b because applicant failed to provide a showing of good ar and was not earlier presented. See 37 CFR 1.116(e). | | | | |
| The affidavit or other evidence filed after the date of filing entered because the affidavit or other evidence failed to showing a good and sufficient reasons why it is necessar | overcome <u>all</u> rejections under apperry and was not earlier presented. | al and/or appellant fa See 37 CFR 41.33(d)(| ils to provide a 1). | |
| 10. The affidavit or other evidence is entered. An explanation of the control | on of the status of the claims after o | entry is below or attac | ched. | |
| 11. The request for reconsideration has been considered by See Continuation Sheet. | ut does NOT place the application i | n condition for allowa | nce because: | |
| 12. Note the attached Information Disclosure Statement(s). (PTO/SB/08 or PTO-1449) Paper No(s). filed 02/22/05 13. Other: | | | | |
| | | | | |
| | | | | |

U.S. Patent and Trademark Office PTOL-303 (Rev. 4-05) Continuation of 5. Applicant's reply has overcome the following rejection(s): 35 U.S.C. 102(b) and 35 U.S.C. 112, first paragraph for written description.

Continuation of 11 does NOT place the application in condition for allowance because: The rejection under 35 U.S.C. 112, first paragraph for new matter over claims 10-38, 41, 44-46 and 48-54 is maintained. Applicant's arguments filed 3/28/05 have been fully considered but they are not persuasive. Applicant argues that the purpose of the written description requirement is to ensure that the inventors had possession of the claimed subject matter, i.e., to ensure that the inventors actually invented what is claimed and for support cites various case laws (See e.g., page 14 of the remark filed 3/28/05). Further, Applicant argues that the specification and claims as originally filed adequately support the amended claim language "who has not been diagnosed with non-insulin dependent diabetes mellitus (NIDDM)" See e.g., specification at page 1, lines 15 to page 2, line 3; page 3, lines 3-10; page 4, lines 1-8; and page 6, lines 1-9; particularly, page 1, line 22 to page 2, line 3, IGT is a distinct condition which may or may not develop into NIDDM. Applicant's instant claims merely clarify that the methods are directed, to treating the condition of IGT. Applicant concludes by stating that based on the examples in the specification, the skilled artisan would recognize that IGT subjects had not been diagnosed with NIDDM, or else they would not have been included in the IGT group but instead placed in the NIDDM group. Accordingly, it is contemplated at the time of the filing as one subject population the treatment of subjects with IGT whose inability to control glucose had not advanced to the point where those subjects were diagnosed with NIDDM. Thus, the specification states the need for a therapy to treat IGT, while acknowledging that studies exist for the application of GLP-1 in case of NIDDM is unpersuasive. Contrary to Applicants, arguments, the above citation or anywhere in the instant specification have no support for the treatment of IGT in a patient who has not been diagnosed with non-insulin dependent diabetes mellitus (NIDDM). The above citations disclosed by Applicant discuss about the prevalence and characterization of IGT and not the negative limitation claimed by Applicant (i.e., who has not been diagnosed with NIDDM). Thus, Applicant's specification demonstrates no intent or concept to include or contemplate the negative limitation of "who has not been diagnosed with NIDDM". The negative limitation is a new concept having no support in the instant specification. Therefore, the rejection under 35 U.S.C. 112, first paragraph for new matter for claims 10-38, 41, 44-46 and 48-54 is maintained for the reasons of record and for the reasons stated above.

JON WEBER

SUPERVISORY PATENT EXAMINER